Results 21 to 30 of about 48,575 (332)

Immunometabolic Modulatory Role of Naltrexone in BV-2 Microglia Cells

International Journal of Molecular Sciences, 2021
Background: Naltrexone is an opioid receptor antagonist commonly used to treat opioid and alcohol dependence. The use of low dose naltrexone (LDN) was found to have anti-inflammatory properties for treatment of diseases such as fibromyalgia, Crohn’s ...
N. Kučić, V. Rački, Roberta Šverko, Toni Vidovic, Irena Grahovac, J. Mršić-Pelčić   +5 more
semanticscholar   +1 more source

Examining the predictive validity of alcohol-seeking following punishment-imposed abstinence in mice. [PDF]

Alcohol Clin Exp Res (Hoboken)
Animal models of alcohol use disorder are critical to understand the neurochemical mechanisms underlying this disorder to inform targeted medication development. However, quite often the validity of commonly used animal models remains untested. Here, we optimized a highly used model of abstinence in mice and demonstrated the predictive validity of the ...
Tran L, Kuznetsova M, Manning EE, Campbell EJ.   +3 more
europepmc   +2 more sources

The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice. [PDF]

, 2015
RATIONALE Using the drinking-in-the-dark (DID) model, we compared the effects of a novel mu-opioid receptor antagonist, GSK1521498, with naltrexone, a licensed treatment of alcohol dependence, on ethanol consumption in mice.
C Giuliano, C Giuliano, David N. Stephens, David R. Wille, DM Ignar, DN Stephens, DW Oslin, EA Rabiner, Edward T. Bullmore, EE Codd, F Kiefer, GH Jones, H Wit de, H Ziauddeen, HM Pettinati, JR Volpicelli, JS Rhodes, Kay Maltby, LA Berner, LA Parker, LD Middaugh, LS Hwa, Manolo Mugnaini, NK Kamdar, P Monti, PJ Nathan, PJ Nathan, Pradeep Nathan, S Loeber, Sam R. Miller, Sandra Sanchez-Roige, Tamzin L. Ripley, TJ Phillips, TL Ripley   +33 more
core   +1 more source

Biodegradable polymeric prodrugs of naltrexone [PDF]

, 1991
The development of a biodegradable polymeric drug delivery system for the narcotic antagonist naltrexone may improve patient compliance in the treatment of opiate addiction. Random copolymers consisting of the ¿-amino acids N5-(3-hydroxypropyl--glutamine
Adams, N.W., Bennet, D.B., Feijen, J., Hoes, C.J.T., Kim, S.W., Li, X.   +5 more
core   +2 more sources

Scalable Production of Highly-Sensitive Nanosensors Based on Graphene Functionalized with a Designed G Protein-Coupled Receptor [PDF]

, 2014
We have developed a novel, all-electronic biosensor for opioids that consists of an engineered mu opioid receptor protein, with high binding affinity for opioids, chemically bonded to a graphene field-effect transistor to read out ligand binding.
Crook, Alexander, Han, Gang Hee, Hong, Sung Ju, Johnson, A. T. Charlie, Lerner, Mitchell B., Liu, Renyu, Matsunaga, Felipe, Park, Yung Woo, Perez-Aguilar, Jose Manuel, Saven, Jeffery G., Xi, Jin   +10 more
core   +4 more sources

Naltrexone-bupropion (Mysimba®) in management of obesity: a systematic review and meta-analysis of unpublished clinical study reports.

British Journal of Clinical Pharmacology, 2020
AIMS To compare the benefits and harms of naltrexone-bupropion using evidence from clinical study reports (CSRs). METHODS We searched FDA and EMA websites, PubMed, and Clinicaltrials.gov (May 2016) to identify pivotal trials; we then sent a freedom of ...
I. Onakpoya, J. Lee, K. Mahtani, J. Aronson, C. Heneghan   +4 more
semanticscholar   +1 more source

Low-dose and high-dose naltrexone in opioid dependence syndrome: a three months outcome study

Open Journal of Psychiatry and Allied Sciences, 2019
Background: Naltrexone is effective in the treatment of opioid dependence syndrome (ODS) as it prevents relapse. To effectively design a cost-effective treatment modality for ODS using naltrexone as low as 25 mg is something which is worth exploring. Aim:
Ajeet Sidana, Subhash Das, Sai Prashant Bansal   +2 more
doaj   +1 more source

Caenorhabditis elegans as a model system to identify therapeutics for alcohol use disorders [PDF]

, 2019
Alcohol use disorders (AUDs) cause serious problems in society and few effective treatments are available. Caenorhabditis elegans (C. elegans) is an excellent invertebrate model to study the neurobiological basis of human behavior with a conserved, fully
Bell, Richard L., Bredhold, Kristin E., Cheong, Mi C., Engleman, Eric A., Katner, Simon N., Neal-Beliveau, Bethany S., Steagall, Kevin B., III   +6 more
core   +1 more source

Low-dose naltrexone as a treatment for chronic fatigue syndrome

BMJ Case Reports, 2020
Naltrexone is used as an off-label treatment in low doses for several chronic immune-modulated disorders in many countries. Although only small-scale clinical trials have been performed, these suggest efficacy in several diseases including Crohn’s ...
M. Bolton, Bryan Paul Chapman, H. van Marwijk   +2 more
semanticscholar   +1 more source

Food-induced behavioral sensitization, its cross-sensitization to cocaine and morphine, pharmacological blockade, and effect on food intake [PDF]

, 2006
Repeated administration of abused drugs sensitizes their stimulant effects and results in a drug-paired environment eliciting conditioned activity. We tested whether food induces similar effects.
Le Merrer, Julie, Stephens, David N
core   +1 more source